These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7905369)

  • 1. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.
    Mörike KE; Roden DM
    Clin Pharmacol Ther; 1994 Jan; 55(1):28-34. PubMed ID: 7905369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
    Edeki TI; He H; Wood AJ
    JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.
    Lee JT; Kroemer HK; Silberstein DJ; Funck-Brentano C; Lineberry MD; Wood AJ; Roden DM; Woosley RL
    N Engl J Med; 1990 Jun; 322(25):1764-8. PubMed ID: 1971708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
    Funck-Brentano C; Kroemer HK; Pavlou H; Woosley RL; Roden DM
    Br J Clin Pharmacol; 1989 Apr; 27(4):435-44. PubMed ID: 2719900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.
    Caporaso NE; Shaw GL
    Arch Intern Med; 1991 Oct; 151(10):1985-92. PubMed ID: 1681790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical beta-adrenergic antagonists and quinidine. A risky interaction.
    Higginbotham EJ
    Arch Ophthalmol; 1996 Jun; 114(6):745-6. PubMed ID: 8639090
    [No Abstract]   [Full Text] [Related]  

  • 9. Mirror, mirror on the wall ... stereochemistry in therapeutics.
    Roden DM
    Circulation; 1994 May; 89(5):2451-3. PubMed ID: 7910122
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.
    Botsch S; Heinkele G; Meese CO; Eichelbaum M; Kroemer HK
    Eur J Clin Pharmacol; 1994; 46(2):133-5. PubMed ID: 8039531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology and beta-blocking efficacy of propafenone.
    Barbey JT
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S41-3. PubMed ID: 1723117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.
    Birgersdotter UM; Wong W; Turgeon J; Roden DM
    Br J Clin Pharmacol; 1992 Mar; 33(3):275-80. PubMed ID: 1576047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
    Jazwinska-Tarnawska E; Orzechowska-Juzwenko K; Niewinski P; Rzemislawska Z; Loboz-Grudzien K; Dmochowska-Perz M; Slawin J
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
    O'Hara GE; Philippon F; Gilbert M; Champagne J; Michaud V; Charbonneau L; Pruneau G; Hamelin BA; Geelen P; Turgeon J
    J Clin Pharmacol; 2012 Feb; 52(2):171-9. PubMed ID: 21508180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propafenone shows class Ic and class II antiarrhythmic effects.
    Stoschitzky K; Stoschitzky G; Lercher P; Brussee H; Lamprecht G; Lindner W
    Europace; 2016 Apr; 18(4):568-71. PubMed ID: 26056191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
    Kroemer HK; Fromm MF; Bühl K; Terefe H; Blaschke G; Eichelbaum M
    Circulation; 1994 May; 89(5):2396-400. PubMed ID: 7910120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
    Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
    Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.